EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death

Jooyoung Lee iD, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye-In An, Yong-Jae Kwon, Hana Jin, Chan-Gi Pack, Inki Kim, Young-In Yoon, Gil-Chun Park, Eun-Kyoung Jwa und 6 weitere

Journal of Cellular and Molecular Medicine · 2024-07 · 28 (14)

DOI: 10.1111/jcmm.18533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 21.07.2024. Verfasst von Jooyoung Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Sorafenib, Liver Neoplasms, Carcinoma, Hepatocellular, Reactive Oxygen Species. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Asan Institute for Life Sciences, Asan Medical Center, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B Virus (HBV) infection significantly elevates the risk of hepatocellular carcinoma (HCC), with the HBV X protein (HBx) playing a crucial role in cancer progression. Sorafenib, the primary therapy for advanced HCC, shows limited effectiveness in HBV‐infected patients due to HBx‐related resistance. Numerous studies have explored combination therapies to overcome this resistance. Sodium diethyldithiocarbamate (DDC), known for its anticancer effects and its inhibition of superoxide dismutase 1 (SOD1), is hypothesized to counteract sorafenib (SF) resistance in HBV‐positive HCCs. Our research demonstrates that combining DDC with SF significantly reduces HBx and SOD1 expressions in HBV‐positive HCC cells and human tissues. This combination therapy disrupts the PI3K/Akt/mTOR signalling pathway and promotes apoptosis by increasing reactive oxygen species (ROS) levels. These cellular changes lead to reduced tumour viability and enhanced sensitivity to SF, as evidenced by the synergistic suppression of tumour growth in xenograft models. Additionally, DDC‐mediated suppression of SOD1 further enhances SF sensitivity in HBV‐positive HCC cells and xenografted animals, thereby inhibiting cancer progression more effectively. These findings suggest that the DDC‐SF combination could serve as a promising strategy for overcoming SF resistance in HBV‐related HCC, potentially optimizing therapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibLiver NeoplasmsCarcinoma, HepatocellularReactive Oxygen SpeciesProto-Oncogene Proteins c-aktSuperoxide Dismutase-1TOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesSignal TransductionHepatitis B virusHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysApoptosisHepatitis BDitiocarbDrug Resistance, NeoplasmMice, NudeCell ProliferationTrans-ActivatorsViral Regulatory and Accessory Proteins

Stichwörter der Autor:innen

Sorafenib resistancedisulfiramhepatitis B virushepatocellular carcinomasuperoxide dismutase

Substanzen

SorafenibReactive Oxygen SpeciesProto-Oncogene Proteins c-aktSuperoxide Dismutase-1TOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesSOD1 protein, humanDitiocarbhepatitis B virus X proteinMTOR protein, human

Autor:innen und Institutionen

  • Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Biochemistry and Molecular Biology, AMIST, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Surgery, Gangneung Asan Hospital, University of Ulsan College of Medicine, Seoul, South Korea.
  • Division of Vascular Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Convergence Medicine Research Center (CREDIT), Asan Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.
  • Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

ORCID-Profile: Jooyoung Lee

Förderung

  • National Research Foundation of Korea
  • Asan Institute for Life Sciences, Asan Medical Center
  • NCI NIH HHS

Zitieren

APA

Lee, J., Kim, J., Lee, R., Lee, E., An, H. I., Kwon, Y. J., Jin, H., Pack, C. G., Kim, I., Yoon, Y. I., Park, G. C., Jwa, E. K., Kwon, J. H., Namgoong, J. M., Song, G. W., Hwang, S., Tak, E., & Lee, S. G. (2024). SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death. Journal of Cellular and Molecular Medicine, 28(14). https://doi.org/10.1111/jcmm.18533

Vancouver

Lee J, Kim J, Lee R, Lee E, An HI, Kwon YJ, et al. SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death. Journal of Cellular and Molecular Medicine. 2024;28(14). doi:10.1111/jcmm.18533

BibTeX
@article{Lee2024,
  author = {Lee, Jooyoung and Kim, Jiye and Lee, Ryunjin and Lee, Eunkyeong and An, Hye-In and Kwon, Yong-Jae and Jin, Hana and Pack, Chan-Gi and Kim, Inki and Yoon, Young-In and Park, Gil-Chun and Jwa, Eun-Kyoung and Kwon, Jae Hyun and Namgoong, Jung-Man and Song, Gi-Won and Hwang, Shin and Tak, Eunyoung and Lee, Sung-Gyu},
  title = {SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  volume = {28},
  number = {14},
  doi = {10.1111/jcmm.18533}
}
Kostenlos starten →